TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03195309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
Study: NCT02707263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous continuous infusion of heparin (IV UFH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Heparin
Study: NCT02845167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Description: Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
Study: NCT03229642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
Study: NCT02001753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMR

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CMR
Study: NCT01879358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Study: NCT01318005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Ortho-Novum® 1/35
Description: Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Ovcon® 35
Description: Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Microgestin Fe® 1/20
Description: Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
Study: NCT02626195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional support program
Description: Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~* Calories: 30-35Kg, via enteral or parenteral~* Protein: 1.2-1.5g/Kg~* Lipid : 1-1.5g/Kg~* Mineral and vitamins supply~* Blood glucose control~* Daily monitoring by dietician and specialized nurse
Study: NCT02758340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women would be given misoprostol tablet by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women would be given misoprostol tablet by mouth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foley's balloon catheter
Description: foley's balloon catheter would be inserted through vagina into cervix.
Study: NCT01318109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
Study: NCT03651596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Messaging Intervention Group
Description: The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard mHealth Messaging Group
Description: Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
Study: NCT04642339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01739179

Intervention type: PROCEDURE
Intervention: VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
Description: Patients in this Study Arm will receive a VP Shunt inserted laparoscopically

Intervention type: PROCEDURE
Intervention: VP Shunt Surgery for open insertion of the peritoneal catheter
Description: Patients in this Study Arm will receive a VP Shunt inserted openly
Study: NCT00419380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa (Pulmozyme®)
Description: This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa (Pulmozyme®)
Description: This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
Study: NCT04430244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty
Description: Deep anterior lamellar keratoplasty using dehydrated corneas

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep anterior lamellar keratoplasty
Description: Deep anterior lamellar keratoplasty using standard organ culture stored corneas
Study: NCT03260387

Intervention type: PROCEDURE
Intervention: TPIAT
Description: The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
Study: NCT00637988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg twice daily
Study: NCT03945708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: Addition of a hemofilter to the cardiopulmonary bypass circuit
Study: NCT01806363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Study: NCT04296370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib; Apatinib
Description: Fluzoparib Orally twice daily; Apatinib Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib Orally twice daily
Study: NCT04296370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Investigators will declare one of the following regimens:~Capecitabine Vinorelbine
Study: NCT00610831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIRECTVIEW CR Mammography
Description: 4 views screening mammogram
Study: NCT00637988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT00689871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery
Study: NCT01154374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO Wound Ointment
Description: Topical application twice daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (sterile saline moistened gauze)
Study: NCT00742768

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 in softgel
Description: 4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 in Gelpell
Description: 4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
Study: NCT02069899

Intervention type: DRUG
Group type: OTHER
Intervention: Emapalumab
Description: Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.

Intervention type: DRUG
Group type: OTHER
Intervention: Emapalumab
Description: Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
Study: NCT00637988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rofecoxib
Description: 25mg once daily
Study: NCT02507167

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mixed meal
Description: 250 ml Fortimel compact (chocolate)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: 250 ml Fortimel compact (chocolate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: oral rifampin administration (600 mg EREMFAT®)
Study: NCT03413501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MUD-PI
Study: NCT01181011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine/telmisartan/combination
Description: patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
Study: NCT02559440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: 50μg, 1 puff in each nostril every evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 puff in each nostril every evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline + Placebo
Description: 1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: 1 puff of placebo +1 puff of Placebo in each nostril every evening
Study: NCT03543228

Intervention type: DIAGNOSTIC_TEST
Intervention: MyoStrain
Description: MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
Study: NCT03158285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
Study: NCT02559440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate + Placebo
Description: 1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate + Oxymetazoline
Description: 1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
Study: NCT03808727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
Study: NCT03158285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
Study: NCT03461328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate
Description: intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
Study: NCT00372502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified EGDT
Description: Early goal directed therapy with lactate clearance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard EGDT
Description: Early goal directed therapy
Study: NCT01548339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: 3 trocars laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: 3 trocars laparoscopic cholecystectomy
Study: NCT03158285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study: NCT01918748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Master
Description: The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
Study: NCT04270370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478045
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478045
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478045
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.
Study: NCT02613026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03464175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo®
Description: Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo®
Description: Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo®
Description: Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo®
Description: Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated-humidified circuit
Description: It will be left on during the transfer and the nebulization in group 1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated-humidified circuit
Description: It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry ventilator circuit specific for aerosol therapy
Description: Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dry ventilator circuit with HME filter
Description: The nebulizer is placed between the filter and the endotracheal tube.
Study: NCT02744040

Intervention type: DRUG
Group type: OTHER
Intervention: ART initiation at time of HIV diagnosis
Description: Immediate ART initiation

Intervention type: DRUG
Group type: OTHER
Intervention: ART at 24 weeks
Description: ART initiation 24 weeks after enrollment
Study: NCT01740453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 2 mg/ml
Description: single
Study: NCT03323567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD Muscle GUNA collagen
Description: intramusclular injections of MD Muscle collagen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: intramuscular Lidocaine 2% injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution, Hypertonic
Description: intramuscular Saline injection
Study: NCT04499352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: BI 754091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: BI 754091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: BI 836880
Study: NCT00886678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, IV, q 21 days x 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5,IV,q 21 days x 2 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation
Description: 66 Gy over 33 fractions
Study: NCT01221311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered Metallic Stent
Description: Covered Wallflex Biliary (TM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Stent
Description: Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
Study: NCT01192009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7.2 g of leucine during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.2 g of alanine during 2 weeks
Study: NCT03913338

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LasikXtra
Description: By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LASIK
Description: Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
Study: NCT00504972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLL1
Description: hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
Study: NCT03702413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Acute thrombectomy